Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 1
2003 2
2005 1
2006 5
2008 1
2009 2
2011 3
2012 3
2013 1
2014 2
2015 4
2016 2
2017 3
2018 3
2019 3
2020 2
2021 1
2022 4
2024 1
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
Steinman L, Fox E, Hartung HP, Alvarez E, Qian P, Wray S, Robertson D, Huang D, Selmaj K, Wynn D, Cutter G, Mok K, Hsu Y, Xu Y, Weiss MS, Bosco JA, Power SA, Lee L, Miskin HP, Cree BAC; ULTIMATE I and ULTIMATE II Investigators. Steinman L, et al. N Engl J Med. 2022 Aug 25;387(8):704-714. doi: 10.1056/NEJMoa2201904. N Engl J Med. 2022. PMID: 36001711 Clinical Trial.
Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis.
Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P, Syed S, Li Y, Vargas WS, Turner TJ, Wallstroem E, Reich DS; HERCULES Trial Group. Fox RJ, et al. N Engl J Med. 2025 May 15;392(19):1883-1892. doi: 10.1056/NEJMoa2415988. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202696 Clinical Trial.
Inhibition of CD40L with Frexalimab in Multiple Sclerosis.
Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G; Frexalimab Phase 2 Trial Group. Vermersch P, et al. N Engl J Med. 2024 Feb 15;390(7):589-600. doi: 10.1056/NEJMoa2309439. N Engl J Med. 2024. PMID: 38354138 Clinical Trial.
Tolebrutinib versus Teriflunomide in Relapsing Multiple Sclerosis.
Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP, Syed S, Chen Y, Maxwell CR, Benoit P, Turner TJ, Wallstroem E, Wiendl H; Tolebrutinib Phase 3 GEMINI 1 and 2 Trial Group. Oh J, et al. N Engl J Med. 2025 May 15;392(19):1893-1904. doi: 10.1056/NEJMoa2415985. Epub 2025 Apr 8. N Engl J Med. 2025. PMID: 40202623 Clinical Trial.
[New directions of immunocorrection in multiple sclerosis].
Boyko AN, Khachanova NV, Melnikov MV, Sivertseva SA, Evdoshenko EP, Spirin NN, Vasilyev AV, Rozenson OL. Boyko AN, et al. Among authors: khachanova nv. Zh Nevrol Psikhiatr Im S S Korsakova. 2020;120(2):103-109. doi: 10.17116/jnevro2020120021103. Zh Nevrol Psikhiatr Im S S Korsakova. 2020. PMID: 32307419 Review. Russian.
[Issues of the current terminology in multiple sclerosis].
Boyko AN, Guseva MR, Khachanova NV, Gusev EI. Boyko AN, et al. Among authors: khachanova nv. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(8. Vyp. 2):121-127. doi: 10.17116/jnevro2018118082121. Zh Nevrol Psikhiatr Im S S Korsakova. 2018. PMID: 30160680 Russian.
Validation of the Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS) in the Russian Population.
Evdoshenko E, Laskova K, Shumilina M, Nekrashevich E, Andreeva M, Neofidov N, Kalinin I, Nikitchenko D, Rogozina A, Kupaeva A, Bulanov I, Bakirtzis C, Grigoriadis N, Khachanova N, Davydovskaya M, Makshakov G. Evdoshenko E, et al. Among authors: khachanova n. J Int Neuropsychol Soc. 2022 May;28(5):503-510. doi: 10.1017/S1355617721000722. Epub 2021 Jun 16. J Int Neuropsychol Soc. 2022. PMID: 34132190
45 results